FDA Inspection Of Genzyme Plant Finds Lack Of Follow-up, Old Equipment, Poor Personnel Qualification
This article was originally published in The Pink Sheet Daily
Executive Summary
A Form 483 posted online by FDA following a five-week inspection of the Allston Landing manufacturing plant cites 49 separate concerns.
You may also be interested in...
Replagal Advisory Committee Will Include Closed Door Session On Manufacturing
FDA’s Cardiovascular and Renal Drugs Advisory Committee will assess Shire biologics’ BLA for the Fabry disease therapy, which already is available in the U.S. due to shortages of competitor Fabrazyme, during a March 27 meeting.
With Activist Investors Looming, Genzyme Takes Preventive Steps
An eventful week at Genzyme concluded with two developments that could keep activist investors and the potential for a proxy fight at bay - a mutual cooperation agreement with a top institutional investor and the hiring of a senior vice president of global product quality
With Activist Investors Looming, Genzyme Takes Preventive Steps
An eventful week at Genzyme concluded with two developments that could keep activist investors and the potential for a proxy fight at bay - a mutual cooperation agreement with a top institutional investor and the hiring of a senior vice president of global product quality